Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.25 CHF | +90.20% |
|
-4.54% | +78.37% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past twelve months, EPS forecast has been revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- Low profitability weakens the company.
- With an enterprise value anticipated at 3.12 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+78.37% | 1.14B | - | ||
+51.63% | 796B | C+ | ||
+41.51% | 628B | B | ||
-5.10% | 358B | C+ | ||
+19.90% | 331B | B- | ||
+9.95% | 301B | C+ | ||
+17.66% | 244B | B+ | ||
+3.39% | 228B | A+ | ||
+10.75% | 214B | B- | ||
+6.99% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PPGN Stock
- 0AAJ Stock
- Ratings PolyPeptide Group AG